Question from Deputy John Clendennen - PQ 21310-26
Deputy Clendennen asked for an update on the accessibility of the drug Givinostat (brand name Duvyzat) for the treatment of Duchenne muscular dystrophy.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy Clendennen asked for an update on the accessibility of the drug Givinostat (brand name Duvyzat) for the treatment of Duchenne muscular dystrophy.
Deputy Aird asked about staffing budget for Midlands Regional Hospital Portlaoise from 2024 to 2026. Read the HSE response.
Deputy Rice asked about the waiting lists for podiatry services. Read the HSE response.
Deputy Rice asked about the waiting lists for audiology services. Read the HSE response.
Deputy Rice asked about CAMHS waiting lists. Read the HSE response.
Deputy Rice asked about waiting lists for ophthalmology services. Read the HSE response.
Deputy Rice asked about waiting lists for occupational therapy services. Read the HSE response.
Deputy Rice asked about the waiting lists for speech and language therapy. Read the HSE response.
Deputy Rice asked about the number of children a waiting list for speech and language therapy. Read the HSE response.
Deputy Sherlock asked about the protocols that are in place for the diagnosis of Lyme’s disease. Read the HSE response.